Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...
Amneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...
Nature2 年
Drug Insight: aminosalicylates for the treatment of IBD
Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease ...
Business Wire5 天
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
(Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for ...
Monthly Prescribing Reference3 年
Mesalamine Delayed-release Tablets
The mechanism of action of mesalamine is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites ...